SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997; 47: 527.
  • 2
    Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology. 2001; 60: 818.
  • 3
    Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 4
    Tempero M, Plunkett W, Ruiz van Haperen V, et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma [abstract 1048]. Proc Am Soc Clin Oncol. 1999; 18: 273a.
  • 5
    Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001; 7: 22462253.
  • 6
    Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51: 61106117.
  • 7
    Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992; 52: 533539.
  • 8
    Eisbruch A, Shewach DS, Urba S, et al. Phase I trial of radiation (RT) concurrent with low-dose gemcitabine (GEM) for head and neck cancer: high mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol. 1997; 16: 1377A.
  • 9
    Coor G, Scalliet P, Van Meerbeak J. A phase II study combining gemcitabine with radiotherapy in stage III NSCLC. Ann Oncol. 1996; 7 (Suppl 5): 101s.
  • 10
    McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer. 2002; 95 (Suppl): 933940.
  • 11
    McGinn CJ, Smith DC, Szarka CE, et al. A phase I study of gemcitabine (GEM) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer [abstract 1014]. Proc Am Soc Clin Oncol. 1998; 17: 264a.
  • 12
    Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999; 17: 22082212.
  • 13
    Blackstock AW, Tempero MA, Niedwiecki D, Hollis DR, Mayer RJ, Tepper JE. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas [abstract 627]. Proc Am Soc Clin Oncol. 2001; 20: 158a.
  • 14
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5: 119127.
  • 15
    Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999; 18: 45544563.
  • 16
    Shi Q, Le X, Abbruzzese JL, et al. Cooperation between transcription factor AP-1 and NF-κB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res. 1999; 19: 13631371.
  • 17
    Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinona. J Interferon Cytokine Res. 2000; 11: 935946.